


### *Amendments to the Claims*

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently Amended) A compound of Formula I:



**I**

or a pharmaceutically acceptable salt thereof, wherein

$R^1$  and  $R^2$  are independently H or  $C_{1-4}$  alkyl, or  $R^1$  and  $R^2$  together form the alkyl ring of a proline or homoproline residue;

$R^3$  is selected from the group consisting of a side chain of an amino acid and a first fluorophore;

$R^4$  is H or  $CH_3$ ;

$R^5$  is H, an amine protecting group, an amino acid residue, a polypeptide, a peptide which contains a second fluorophore, a chemical moiety bound to a solid support, or a moiety containing from about 1 to about 50 non-hydrogen atoms;

$R^6$  is an isoleucine side chain or a valine side chain;

W is O or NH;


X is O [[or NH]]; and

Y is H or a hydroxyl protecting group;

Z is C(O) or C(O)-CH(CH<sub>3</sub>)-C(O);

provided that [[if]] when  $R^1$  and  $R^2$  together form the alkyl ring of a proline residue, then  $R^4$  is [[methyl]] H, and X is O, ~~then  $R^3$  is naphthylmethyl.~~

2. (Currently Amended) The compound according to claim 1 having the formula



or a pharmaceutically acceptable salt thereof, wherein

$R^1$  and  $R^2$  are independently H or C<sub>1-4</sub> alkyl, or  $R^1$  and  $R^2$  together form the alkyl ring of a proline residue;

$R^3$  is selected from the group consisting of a side chain of an amino acid and a first fluorophore;

$R^4$  is H or  $CH_3$ ;

$R^5$  is H, an amine protecting group, an amino acid residue, a polypeptide, a peptide which contains a second fluorophore, a chemical moiety bound to a solid support, or a moiety containing from about 1 to about 50 non-hydrogen atoms;

$R^6$  is an isoleucine side chain or a valine side chain;

X is O [[or NH]]; and

Y is H or a hydroxyl protecting group;

provided that [[if]] when  $R^1$  and  $R^2$  together form the alkyl ring of a proline residue, then  $R^4$  is [[methyl]] H, and ~~X is O, then  $R^3$  is naphthylmethyl.~~

3. (Original) The compound according to claim 2, wherein  $R^1$  is H and  $R^2$  is methyl.

4. (Original; Withdrawn) The compound according to claim 2, wherein  $R^1$  and  $R^2$  are methyl.

5. (Original; Withdrawn) The compound according to claim 2, wherein  $R^1$  and  $R^2$  together form the alkyl ring of a proline residue.

6. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>3</sup> is a side chain of an amino acid.

7. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>3</sup> is naphthylmethyl.

8. (Original) The compound according to claim 2, wherein R<sup>3</sup> is a benzyl group optionally substituted with OH, OCH<sub>3</sub>, CO(C<sub>6</sub>H<sub>5</sub>), F, Cl, Br, I, CH<sub>3</sub>, or C<sub>2</sub>H<sub>5</sub>.

9. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>3</sup> contains a fluorophore.

10. (Original) The compound according to claim 2, wherein R<sup>4</sup> is CH<sub>3</sub>.

11. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>4</sup> is H.

12. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>5</sup> is H.

13. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>5</sup> is an amine protecting group.

14. (Original) The compound according to claim 2, wherein R<sup>5</sup> is an amino acid residue or a polypeptide.

15. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>5</sup> contains a fluorophore.

16. (Original) The compound according to claim 2, wherein R<sup>5</sup> is selected from the group consisting of -(*N*-methyl)leucine;

-(*N*-methyl)leucine-proline;

-(*N*-CBz-*N*-methyl)leucine;

-(*N*-methyl)leucine-proline-lactate;

-(*N*-methyl)leucine-proline-pyruvate;

-(*N*-methyl)leucine-proline-lactate-glutamine-pyroglutamate;

-(*N*-methyl)leucine-proline-lactate-glutamine-cyclopentanoate;

-(*N*-methyl)leucine-proline-lactate-leucine-pyroglutamate;

-(*N*-methyl)leucine-proline-lactate-glutamine-cyclopentanoate;

-(*N*-methyl)leucine-proline-alanine-leucine-pyroglutamate, and

-(*N*-methyl)leucine-proline-(*N*-methyl)alanine-leucine-pyroglutamate.

17. (Original) The compound according to claim 2, wherein R<sup>6</sup> is a valine side chain.

18. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>6</sup> is a leucine side chain.

19. (Original) The compound according to claim 2, wherein Y is H.

20. (Original; Withdrawn) The compound according to claim 2, wherein Y is a hydroxyl protecting group.

21-22. (Cancelled)

23. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>1</sup> and R<sup>2</sup> together form the alkyl ring of a proline residue; R<sup>3</sup> is a benzyl group optionally substituted with one or more selected from the group consisting of OH, OCH<sub>3</sub>, CO(C<sub>6</sub>H<sub>5</sub>), F, Cl, Br, I, CH<sub>3</sub>, and C<sub>2</sub>H<sub>5</sub>; R<sup>4</sup> is H; R<sup>6</sup> is a valine side chain; X is O; and Y is H.


24. (Original) The compound according to claim 2, wherein R<sup>1</sup> is H; R<sup>2</sup> is CH<sub>3</sub>; R<sup>3</sup> is a benzyl group optionally substituted with one or more selected from the group consisting of OH, OCH<sub>3</sub>, CO(C<sub>6</sub>H<sub>5</sub>), F, Cl, Br, I, CH<sub>3</sub>, and C<sub>2</sub>H<sub>5</sub>; R<sup>4</sup> is CH<sub>3</sub>; R<sup>5</sup> is as defined above; R<sup>6</sup> is a valine side chain; X is O; and Y is H.

25. (Original; Withdrawn) The compound according to claim 2, wherein R<sup>1</sup> is CH<sub>3</sub>; R<sup>2</sup> is CH<sub>3</sub>; R<sup>3</sup> is a benzyl group optionally substituted with one or more selected from the group consisting of OH, OCH<sub>3</sub>, CO(C<sub>6</sub>H<sub>5</sub>), F, Cl, Br, I, CH<sub>3</sub>, and C<sub>2</sub>H<sub>5</sub>, preferably OCH<sub>3</sub>; R<sup>4</sup> is CH<sub>3</sub>; R<sup>6</sup> is a valine side chain; X is O; and Y is H.

26. (Cancelled)


27. (Original) The compound according to claim 2, wherein R<sup>5</sup> consists of 1-5 amino acid residues.

28. (Currently Amended; Withdrawn) The compound according to claim 2,  
having the structure




or a pharmaceutically acceptable salt thereof.

29. (Currently Amended; Withdrawn) The compound according to claim 2,  
having the structure




or a pharmaceutically acceptable salt thereof.

30. (Currently Amended) The compound according to claim 2, having the structure



or a pharmaceutically acceptable salt thereof.

31. (Currently Amended) The compound according to claim 2, having the structure




or a pharmaceutically acceptable salt thereof.

32. (Cancelled)

33. (Currently Amended; Withdrawn) A compound having the structure





34. (Previously Presented) A composition comprising a compound according to claim 1 and a pharmaceutically compatible excipient or carrier.

35. (Previously Presented; Withdrawn) A method of inhibiting, treating, or preventing tumorigenesis, comprising contacting a cell with an effective amount of a compound according to claim 1.

36. (Previously Presented; Withdrawn) A method of preventing or inhibiting the growth of a cancer cell, comprising contacting a cancer cell with an effective amount of a compound according to claim 1.

37. (Previously Presented; Withdrawn) A method of inhibiting or preventing protein synthesis, comprising contacting a cell or cellular component with an effective amount of a compound of claim 1.

38. (Previously Presented; Withdrawn) A method of enhancing apoptosis, comprising contacting a cell or cellular component with an effective amount of a compound according to claim 1.

39. (Previously Presented; Withdrawn) A method of providing immunosuppressive therapy, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.